Alirocumab Injection

Alisizumab is a fully human monoclonal antibody (IgG1 isotype) used primarily for the prevention of cardiovascular events and the regulation of primary hypercholesterolemia (including heterozygous familial and non-familial) and mixed dyslipidemia.
In adult patients diagnosed with atherosclerotic cardiovascular disease, it can reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization.
It can be used as an adjunct to diet for the treatment of adult patients with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia to reduce low-density lipoprotein cholesterol (LDL-C) levels.